Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

about

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

Item

http://www.wikidata.org/entity/Q52878728

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@en

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@nl

type

Item

label

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@en

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@nl

prefLabel

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@en

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@nl

P1476

Putative Biomarkers of Response to Treatment in Breast Cancer Patients: A Pilot Assay.

@en

P2093

Ana Lía Nocito

http://www.w3.org/2001/XMLSchema#string

Carlos M Alasino

http://www.w3.org/2001/XMLSchema#string

Cintia Herrera

http://www.w3.org/2001/XMLSchema#string

Eduardo A Roggero

http://www.w3.org/2001/XMLSchema#string

Herman A Perroud

http://www.w3.org/2001/XMLSchema#string

María J Rico

http://www.w3.org/2001/XMLSchema#string

O Graciela Scharovsky

http://www.w3.org/2001/XMLSchema#string

Stella M Pezzotto

http://www.w3.org/2001/XMLSchema#string

Viviana R Rozados

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of tumor-infiltrating FoxP3+ regulatory T cells in cancers: a systematic review and meta-analysis

Stroma-associated master regulators of molecular subtypes predict patient prognosis in ovarian cancer.

Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion

Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression

Heterogeneity for stem cell-related markers according to tumor subtype and histologic stage in breast cancer.

Endothelial induced EMT in breast epithelial cells with stem cell properties

Targeting immune suppressing myeloid-derived suppressor cells in oncology.

Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor-positive, HER2-normal, grade II, lymph node-negative breast cancers.

Leukocytes in mammary development and cancer.

Immature myeloid cells and cancer-associated immune suppression.

P304

377-385

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1080/07357907.2017.1309545

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-04-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28426268

http://www.w3.org/2001/XMLSchema#string